Amarin Corporation plc (NASDAQ:AMRN) today announced the
appointment of Adam Berger and Geraldine Murphy as independent
members of the Company’s Board of Directors, effective immediately.
The Company also announced that, as part of their planned
retirement, Lars Ekman, M.D., Ph.D and Patrick O’Sullivan,
directors of Amarin since 2008 and 2011, respectively, will retire
from the Board, effective at the end of the year. With these
changes, the Amarin Board will remain at eight directors, seven of
whom are independent and five of whom have been appointed in the
past year as part of the Board replenishment process which seeks to
add international experience to support the company’s global
expansion efforts.
“We are delighted to appoint two highly respected,
results-driven leaders with long and proven track records of
success in the fields of healthcare and finance,” said Per
Wold-Olsen, Chairman of the Amarin Board of Directors. “Today’s
appointments represent further progress under our ongoing Board
refreshment program, which is advancing our Board’s collective
expertise and ensures we have the right skillsets to support
Amarin’s new strategic priorities. As Amarin continues to refocus
and execute on its global strategic plan, we are confident that
Geraldine and Adam bring important perspectives and expertise that
will add important value to the Company as we work to generate
shareholder value.”
Mr. Wold-Olsen continued, “On behalf of the entire
Board, I also want to express our deep gratitude to Lars and Paddy
for their leadership, tenure, and dedication to the Amarin Board.
We thank them for their significant contributions to Amarin over
the years’.
Mr. Berger has more than three decades of
experience with investment banking focused on mergers and
acquisitions. He has advised on over 180 announced M&A
transactions predominantly in the healthcare industry totaling more
than $400 billion in value and has significant experience with
capital markets transactions and generating value for company
shareholders. Mr. Berger also brings a unique perspective and skill
set as a former Chairman of Wells Fargo’s Investment Banking
Opinion Committee.
Ms. Murphy brings more than 30 years of experience
as a healthcare company executive across core business areas
including manufacturing, supply chain, P&L management, and
commercial strategy. Ms. Murphy has a strong focus on people and
organizational development which will be of significant value to
Amarin and the Amarin Board.
About Adam Berger
Mr. Berger currently serves as Managing Partner of
Three Peaks Partners, where he provides financial advisory services
to healthcare companies. Mr. Berger has advised a wide range of
corporate M&A, including both domestic and international
transactions in the healthcare space. He has worked with and
advised CEOs, Boards of Directors, and Board committees on various
aspects of transactions, including deal strategy and tactics, deal
structure, terms, and the exploration of strategic
alternatives.
Prior to Three Peaks Partners, Mr. Berger served as
Managing Director and Head of Healthcare M&A at Wells Fargo
Securities. He also served as the Chairman of Wells Fargo’s
Investment Banking Opinion Committee, leading a group of senior
M&A bankers with responsibility for reviewing the firm’s most
sensitive M&A transactions, including determining the firm’s
valuation policies and guidelines and evaluating the possible
issuance of fairness opinions.
Prior to joining Wells Fargo in 2011, Mr. Berger
led the Healthcare M&A effort at Citigroup and was head of
Leerink’s M&A group, after working for many years in Salomon
Brothers M&A group. Mr. Berger has advised many leading
companies in the healthcare industry.
About Geraldine Murphy
Ms. Murphy – an Irish National - currently serves
as Founder and Managing Partner of Evolution-Partners, where she
provides strategic counsel to executive teams as they evolve during
periods of transformation and significant change to support
delivering revenue and profit growth. Ms. Murphy is an accomplished
leader in the biopharmaceutical industry with a demonstrated
ability to deliver outstanding results in complex, highly regulated
environments. She possesses more than 30 years of pharmaceutical
executive experience across core business areas including
manufacturing, supply chain, P&L management, commercial
strategy development and business transformation.
With a background in science and business and with
a deep understanding of governance and regulatory environments in
pharma, Ms. Murphy has demonstrated strong collaboration and
influencing skills through involvement in high-profile pan-EU
projects requiring consensus and alignment across multiple
stakeholders. Ms. Murphy has led international operations across
U.K., Europe, Canada, and Australia, delivering significant revenue
and profit growth while building key partnerships with regulatory,
customer and employee stakeholders. Ms. Murphy is a past member of
the Irish Pharmaceutical Healthcare Association (2009-2012) and
negotiating team who secured a landmark 4-year supply agreement
with the Department of Health. She is a past member of the
Association of British Pharmaceutical Industries (ABPI) DoH supply
agreement reference group (2013).
About Amarin
Amarin is an innovative pharmaceutical company
leading a new paradigm in cardiovascular disease management. From
our scientific research foundation to our focus on clinical trials,
and now our global commercial expansion, we are evolving and
growing rapidly. Amarin has offices in Bridgewater, New Jersey in
the United States, Dublin, in Ireland, Zug in Switzerland, and
other countries in Europe as well as commercial partners and
suppliers around the world. We are committed to rethinking
cardiovascular risk through the advancement of scientific
understanding of the impact on society of significant residual risk
that exists beyond traditional therapies, such as statins for
cholesterol management.
Availability of Other Information About
Amarin
Amarin communicates with its investors and the
public using the company website (www.amarincorp.com) and the
investor relations website (investor.amarincorp.com), including but
not limited to investor presentations and FAQs, Securities and
Exchange Commission (“SEC”) filings, press releases, public
conference calls and webcasts. The information that Amarin posts on
these channels and websites could be deemed to be material
information. As a result, Amarin encourages investors, the media
and others interested in Amarin to review the information that is
posted on these channels, including the investor relations website,
on a regular basis. This list of channels may be updated from time
to time on Amarin’s investor relations website and may include
social media channels. The contents of Amarin’s website or these
channels, or any other website that may be accessed from its
website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of U.S. securities laws. These
forward-looking statements are not promises or guarantees and
involve substantial risks and uncertainties. A list and description
of these risks, uncertainties and other risks associated with an
investment in Amarin can be found in Amarin's filings with the SEC,
including Amarin’s annual report on Form 10-K for the year ended
December 31, 2021, and quarterly report on Form 10-Q for the
quarter ended June 30, 2022. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date they are made. Amarin
undertakes no obligation to update or revise the information
contained in its forward-looking statements, whether as a result of
new information, future events or circumstances or otherwise.
Amarin’s forward-looking statements do not reflect the potential
impact of significant transactions the company may enter into, such
as mergers, acquisitions, dispositions, joint ventures or any
material agreements that Amarin may enter into, amend or
terminate.
Amarin Contact Information
Investor Inquiries:Investor Relations Amarin
Corporation plcinvestor.relations@amarincorp.com
Media Inquiries:Corporate Communications, Amarin
Corporation plcPR@amarincorp.com
or
Matt Sherman / Steve Frankel / Tali EpsteinJoele
Frank, Wilkinson Brimmer Katcher212-355-4449
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024